Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
ProHealth's BPC-157 Ultra Probiotic combines a prebiotic, direct butyrate source, butyrate-producing probiotic, and the peptide BPC-157 in a fully disclosed formulation with third-party verification. The product targets butyrate production and gut barrier function, though human clinical evidence for BPC-157 remains limited to animal models and it carries regulatory uncertainty.
Resbiotic has launched a direct-to-consumer microbiome test using shotgun metagenomics sequencing, offering personalized reports on microbial diversity, gut inflammation markers, intestinal permeability, and keystone bacterial strains. The test integrates with the company's probiotic formulas, enabling consumers to track microbiome changes over 60- to 90-day intervals and adjust supplementation based on longitudinal data.
Aging reduces vaccine efficacy through two interconnected mechanisms: disruption of gut microbial composition and dysregulated mTOR signaling. Restoring microbial diversity and moderating mTOR activity represent tractable targets for improving immune protection in older adults.
Nourish, an AI-assisted nutrition clinic, secured $100 million in Series C funding to scale a model treating chronic disease through behavior change and dietitian-led care rather than medication alone. The company addresses a critical gap in healthcare: chronic conditions develop through years of metabolic drift, yet most interventions remain reactive rather than preventive, with behavioral sustainability determining long-term outcomes.
China has launched a standardized, competency-based education programme in longevity medicine for physicians, representing a systematic shift from reactive disease treatment to proactive healthspan management. This credential-granting initiative integrates geroscience, preventive care, digital technologies, and personalized interventions across multiple medical specialties to address age-related health challenges at scale.
A Phase 1b trial demonstrated that MB097, a multi-strain bacterial therapeutic, restored immunotherapy responsiveness in melanoma patients with primary anti-PD-1 resistance. The finding establishes the microbiome as a targetable factor in cancer immunotherapy, with implications for understanding how microbial ecology shapes immune competence across disease states.
Repair Biotechnologies has developed REP-0004, an mRNA therapy delivered via lipid nanoparticles to the liver, designed to reduce excess intracellular free cholesterol and trigger systemic cholesterol drainage. The drug has received orphan drug designation and aims to enter clinical trials by mid-2027, with preclinical data suggesting rapid regression of atherosclerotic plaque and reversal of metabolic liver disease.
Fasting-mimicking diets trigger autophagy and cellular regeneration through a precise five-day protocol, with clinical evidence demonstrating reversal of insulin resistance and reduced medication dependency in metabolic disease. The mechanism operates as a repair system distinct from emergency symptom management—the body's inherent capacity to reorganize damaged tissue during the refeeding phase.
Fractyl Health has received regulatory approval to initiate Phase 1/2 trials of RJVA-001, a single-administration gene therapy designed to enable patients' own cells to produce GLP-1 indefinitely. This represents a shift toward durable metabolic interventions that require one-time dosing rather than ongoing pharmaceutical management.
A controlled feeding study in young men demonstrates that ultra-processed food consumption impairs sperm quality and reproductive hormone profiles within weeks, independent of weight gain. This finding clarifies a direct mechanistic pathway between food quality and male fertility—a critical but underexplored link in longevity-focused clinical practice.
MBX Biosciences reported early Phase 1 data for MBX 4291, a monthly injection designed to deliver steady drug release with reduced gastrointestinal side effects compared to current weekly GLP-1 treatments. The approach addresses a critical barrier to treatment sustainability: adherence through improved tolerability and dosing convenience.
Aging drives dysregulation of microRNA-152 in the small intestine, which impairs Paneth cells by suppressing mitochondrial function—specifically through reduced expression of Prohibitin1. This mechanism directly compromises intestinal barrier integrity and increases vulnerability to infection and injury in older adults.